Cancer Advances is dedicated to pioneering new medicines and redefining possibilities for cancer patients.

Advancing Cancer Therapy

Our goal is to improve the quality of life and to extend the survival of patients with gastrointestinal cancers. Currently, Cancer Advances is focused on developing therapeutics for gastrin/ gastrin receptor (CCKB) producing tumors. The company's lead product, Polyclonal Antibody Stimulator (PAS), is an immunomodulator that blocks the function of gastrin. This inhibition slows tumor growth, the incidence of metastasis, and also changes the tumor microenvironment.